Sorry, we were unable to verify the authenticity of this link. If you would like to proceed anyway, click the link below.

https://www.gov.uk/drug-safety-update/denosumab-xgeva-for-advanced-malignancies-involving-bone-study-data-show-new-primary-malignancies-reported-more-frequently-compared-to-zoledronate